A detailed history of Wealthspire Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wealthspire Advisors, LLC holds 633 shares of VRTX stock, worth $318,050. This represents 0.0% of its overall portfolio holdings.

Number of Shares
633
Previous 741 14.57%
Holding current value
$318,050
Previous $309,000 4.21%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$392.81 - $485.53 $42,423 - $52,437
-108 Reduced 14.57%
633 $296,000
Q1 2024

May 06, 2024

SELL
$407.69 - $446.08 $92,953 - $101,706
-228 Reduced 23.53%
741 $309,000
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $106,330 - $127,310
310 Added 47.04%
969 $394,000
Q3 2023

Nov 06, 2023

SELL
$338.18 - $362.46 $338 - $362
-1 Reduced 0.15%
659 $229,000
Q2 2023

Jul 31, 2023

BUY
$314.42 - $351.91 $207,517 - $232,260
660 New
660 $232,000
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $238,038 - $267,792
833 New
833 $240,000
Q2 2021

Aug 13, 2021

SELL
$187.49 - $221.1 $508,847 - $600,065
-2,714 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $18,217 - $21,235
-88 Reduced 3.14%
2,714 $583,000
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $164,365 - $219,215
794 Added 39.54%
2,802 $662,000
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $29,911 - $35,462
117 Added 6.19%
2,008 $546,000
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $98,760 - $129,560
-438 Reduced 18.81%
1,891 $549,000
Q1 2020

May 12, 2020

BUY
$199.77 - $247.81 $266,692 - $330,826
1,335 Added 134.31%
2,329 $554,000
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $165,709 - $222,566
994 New
994 $218,000
Q1 2019

May 08, 2019

SELL
$163.73 - $194.7 $36,020 - $42,834
-220 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $33,420 - $42,286
220 New
220 $36,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Wealthspire Advisors, LLC Portfolio

Follow Wealthspire Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealthspire Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealthspire Advisors, LLC with notifications on news.